

Applicants: Peter S. Linsley et al.
U.S. Serial No.: Not yet known
Filed: Herewith
Page 2

considered as illustrative and not restrictive. The scope of the present invention is as set forth in the appended claims rather than being limited to the examples contained in the foregoing description.", and add that same paragraph at page 75, line 9.

In the Claims:

Please add new claims 38-42 as follows:

Sub D24/
--38. A method for regulating functional CTLA4 positive T cell interactions with B7 positive cells comprising contacting the CTLA4 positive cells with a ligand for CTLA4, in an amount effective to interfere with reaction of endogenous B7 antigen with the CTLA4 positive cells.--

1
D
--39. The method of claim 38, wherein the ligand for CTLA4 is a soluble B7 protein.--

Sub D25/
--40. The method of claim 39, wherein the soluble B7 protein is a B7Ig fusion protein.--

--41. The method of claim 38, wherein the ligand for CTLA4 is a monoclonal antibody reactive with CTLA4.--

--42. The method of claim 38, wherein the ligand for CTLA4 is a Fab or F(ab')₂ antibody fragment reactive with CTLA4.--

Please cancel claims 1-10, and 20-37 without prejudice.